X
Standing on the cusp of something great: How real-world data is poised to transform cancer care
https://pharmaphorum.com/whitepapers/standing-cusp-something-great-real-world-data-poised-transform-cancer-care/
Drug regulation
Despite progress, Brexit still threatens UK with relegation to second division
With time running out on Brexit, companies are already making long-term decisions.
Accessing biosimilars: untapped potential in EU and US
Though they can reduce the costs of health care, biosimilars still face challenges to access.
Huge scale of Brexit threat to Europe’s medicines supplies revealed
New survey reveals the huge task facing pharma in keeping medicines moving around Europe after Brexit.
PRIME movers: taking stock of the EMA’s scheme
Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
New UK law to control generic drug prices – implications for pharma
The aims and implications of the Health Service Medical Supplies (Costs) Act 2017.
